enGene (NASDAQ:ENGN) & Rezolute (NASDAQ:RZLT) Critical Review

Rezolute (NASDAQ:RZLT) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Volatility and Risk

Rezolute has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Rezolute and enGene, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1	3	8	0	2.58
enGene	2	8	4	0	2.14

Rezolute currently has a consensus price target of $9.38, suggesting a potential upside of 108.94%. enGene has a consensus price target of $11.05, suggesting a potential upside of 482.87%. Given enGene’s higher probable upside, analysts plainly believe enGene is more favorable than Rezolute.

Valuation and Earnings

This table compares Rezolute and enGene”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41 million	($0.82)	-5.47
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.87

Rezolute is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.0% of Rezolute shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Rezolute and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
enGene	N/A	-56.06%	-45.64%

Summary

Rezolute beats enGene on 7 of the 11 factors compared between the two stocks.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.